drugset / Trial / NCT02151149
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
RandomizedParallel-groupOpen-labelTreatment
Summary
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Timeline
- Start
- 2014-06-09
- Primary completion
- 2017-07-14
- Completion
- 2017-07-14
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
registry p = 0.9258; Risk Ratio (RR) 1.01 (95% CI 0.84 to 1.21) NCT02151149 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | Intravenous |